Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 2586512, 6 pages
http://dx.doi.org/10.1155/2016/2586512
Research Article

Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

1Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
2Department of Nuclear Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
3Department of Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Received 13 April 2016; Accepted 14 September 2016

Academic Editor: Diego Russo

Copyright © 2016 Pablo Florenzano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. E. L. Mazzaferri and R. T. Kloos, “Current approaches to primary therapy for papillary and follicular thyroid cancer,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1447–1463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Lamartina, C. Durante, S. Filetti, and D. S. Cooper, “Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 5, pp. 1748–1761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Carhill, D. R. Litofsky, D. S. Ross et al., “Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012,” The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 9, pp. 3270–3279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ballal, R. Soundararajan, A. Garg, S. Chopra, and C. Bal, “Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study,” Clinical Endocrinology, vol. 84, no. 3, pp. 408–416, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Y. Wang, F. L. Palmer, J. C. Migliacci et al., “Role of RAI in the management of incidental N1a disease in papillary thyroid cancer,” Clinical Endocrinology, vol. 84, no. 2, pp. 292–295, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Pitoia, L. Ward, N. Wohllk et al., “Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 53, no. 7, pp. 884–897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. R. M. Tuttle, R. I. Haddad, D. W. Ball et al., “Thyroid carcinoma, version 2. 2014,” Journal of the National Comprehensive Cancer Network, vol. 12, no. 12, pp. 1671–1680, 2014. View at Google Scholar
  9. C. Rubino, F. de Vathaire, M. E. Dottorini et al., “Second primary malignancies in thyroid cancer patients,” British Journal of Cancer, vol. 89, no. 9, pp. 1638–1644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. N. G. Iyer, L. G. T. Morris, R. M. Tuttle, A. R. Shaha, and I. Ganly, “Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy,” Cancer, vol. 117, no. 19, pp. 4439–4446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Dohán, A. De La Vieja, V. Paroder et al., “The sodium/iodide symporter (NIS): characterization, regulation, and medical significance,” Endocrine Reviews, vol. 24, no. 1, pp. 48–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Jonklaas, H. Wang, and G. Esposito, “Salivary function after radioiodine therapy: poor correlation between symptoms and salivary scintigraphy,” Frontiers in Endocrinology, vol. 6, article 100, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. K. Grewal, S. M. Larson, C. E. Pentlow et al., “Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation,” Journal of Nuclear Medicine, vol. 50, no. 10, pp. 1605–1610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Mendoza, B. Shaffer, D. Karakla, M. E. Mason, D. Elkins, and T. E. Goffman, “Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction,” Thyroid, vol. 14, no. 2, pp. 133–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Zettinig, G. Hanselmayer, B. J. Fueger et al., “Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 29, no. 11, pp. 1428–1432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Jonklaas, “Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction,” Thyroid, vol. 24, no. 12, pp. 1806–1814, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Haymart, M. Banerjee, A. K. Stewart, R. J. Koenig, J. D. Birkmeyer, and J. J. Griggs, “Use of radioactive iodine for thyroid cancer,” Journal of the American Medical Association, vol. 306, no. 7, pp. 721–728, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. S. Lee, H.-S. Chang, and C. S. Park, “Changing trends in the management of well-differentiated thyroid carcinoma in Korea,” Endocrine Journal, vol. 63, no. 6, pp. 515–521, 2016. View at Publisher · View at Google Scholar
  19. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D. S. Cooper, G. M. Doherty et al., “Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–214, 2009. View at Publisher · View at Google Scholar
  20. M. Schlumberger, B. Catargi, I. Borget et al., “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Mallick, C. Harmer, B. Yap et al., “Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1674–1685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Applewhite, B. C. James, S. P. Kaplan et al., “Quality of life in thyroid cancer is similar to that of other cancers with worse survival,” World Journal of Surgery, vol. 40, no. 3, pp. 551–561, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Aschebrook-Kilfoy, B. James, S. Nagar et al., “Risk factors for decreased quality of life in thyroid cancer survivors: initial findings from the north American thyroid cancer survivorship study,” Thyroid, vol. 25, no. 12, pp. 1313–1321, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kammori, T. Fukumori, Y. Sugishita, M. Hoshi, and T. Yamada, “Therapeutic strategy for low-risk thyroid cancer in Kanaji thyroid hospital,” Endocrine Journal, vol. 61, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus